(PT) because previous investigators had found that the most specific effect of anti-PL antibodies was to block the activation of prothrombin by the prothrombin activator complex of factors Xa, V, calcium, and phospholipids. "' "Subsequently it was shown that the (activated) partial thromboplastin time ((A)PTT) was more sensitive for LAC than the PT. A prolongation in the (A)PTT that is not correctable by 1:1 mixing with normal sera indicates the presence of LAC, provided that activities of individual coagulation factors are normal.9 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Influences of the source'4 '5 and concentration9 [16] [17] [18] [19] [16] [17] [18] [19] [20] [21] [22] The association between LAC and biological false positive tests for syphilis on one hand and data indicating that cardiolipin is the principal antigen in these precipitation tests on the other, led to the introduction of solid phase immunoassays with cardiolipin as an antigen.' 23 Since the demonstration that raised ACA levels correlate both with LAC and with a history of thrombosis, fetal loss, and thrombocytopenia1 6 24 the ACA-ELISA is widely used. Studies on differences between various anti-PL antibody assays with respect to their potential for identifying patients with particular clinical features are rare. Therefore, we compared in 111 patients with systemic lupus erythematosus (SLE) or lupus-like disease, the sensitivity, specificity, and detection rate of four different LAC assays, the ACA-ELISA, and combinations of these with respect to recognition of the subset of patients with thrombosis, fetal loss, and/or thrombocytopenia. Patients 10 minutes to obtain platelet-poor plasma.
Blood samples for serum tests were obtained by venipuncture and collected into glass tubes without anticoagulants, at the same time as the platelet-poor plasma samples were drawn. The blood was allowed to clot at room temperature and then centrifuged at 175 g for 10 minutes to obtain serum.
Both platelet-poor plasma and serum were stored in small aliquots at -80°C until use. None of the patients was treated with heparin at the time of blood sampling.
Normal control blood samples were taken from healthy hospital workers with a median age of 29 years (range 23-46).
ASSAYS FOR LUPUS ANTICOAGULANT
PTTsystem with partial thromboplastin derivedfrom animal (monkey and rabbit) brain (PTT-st) Test plasma (0-05 ml) was mixed with 0-05 ml control plasma in a glass tube (at 37°C). Immediately after mixing 0-1 ml commercial PTT reagent derived from monkey and rabbit brain (Boehringer, Mannheim, FRG) was added, mixed, and incubated for three minutes at 37°C. CaC12 25 mmol/l (0.1 ml) was then added and the clotting time was measured in duplicate (tilt tube method). A prolongation of the PIT by more than five seconds above that of pooled control plasma tested simultaneously indicated the presence of LAC. The normal value with pooled control plasma was 35 (5) s (mean (2SD) of 50 tests).
PTT system with partial thromboplastin derivedfrom human brain (PTT-HB) A partial thromboplastin was prepared in our laboratory according to the method of Hjort et al,27 using human crude brain extract. Test plasma (0-05 ml) was mixed with 0-05 ml control plasma in a glass tube at 37°C. Immediately after mixing 0-1 ml clotting time measured in duplicate (tilt tube method). A prolongation of the PTT by more than 10 seconds above that of pooled control plasma tested simultaneously indicated the presence of LAC. The normal value with pooled control plasma was 55 (10) London29: for IgG ACA low positive (mean (2SD) units<80); medium positive (80<units<185); high positive (units>185); for IgM ACA low positive (mean (2SD)<units<25); medium positive (25< units<200); high positive (units>200).
Intra-assay coefficients of variation, obtained by testing four dilutions of the standard sample (ACA levels of these dilutions covered the entire range of the assay) on the same plate 12 times, were found to be 6-4%, 7-1%, 3-4%, and 3-1% for IgG ACA and 10-6%, 9-0%, 4-4%, and 4-8% for IgM ACA. Interassay coefficients of variation expressed in units were calculated from 10 different assays during a period of two months. These were 14*8%, 9.5%, 10-4%, and 5*3% for IgG ACA and 14-6%, 10-2%, 8-6%, and 7-4% for IgM ACA.
PLATELET COUNTS Blood platelets were counted in edetic acid-blood by the Coulter counter method.
CALCULATIONS
The x2 test was used for statistical analysis. For evaluation the following definitions were used3t: sensitivity-the probability that the test result will be positive when the patient has the particular symptom, or (true positive/(true positive+false negative)) x 100%; specificity-the probability that the result will be negative when the symptom is not present, or (true negative/(true negative+false positive))x 100%; detection rate-the probability that the particular symptom will be present when the test result is positive, or (true positive/(true positive+ false positive)) x 100%.
Results

PREVALENCE OF ANTI-PL ANTIBODIES
In 47/111 patients at least one LAC assay was positive. Four positive LAC assays were found in 19 patients and three positive assays in seven patients (PL dilution negative (n=3), KCT negative (n=2), PTT-HB negative (n=1), PTT-st negative (n=1)). In five patients two LAC assays were positive (PIT-HB and PTT-st (n=2), PTT-HB and PL dilution (n=1), PIT-st and KCT (n=1), PTT-st and PL dilution (n=1)), and in 16 patients only one assay was positive (PTF-st (n=13), PL dilution (n=3)). Prevalences of a positive PIT-st, PTT Twenty six patients had a history of thrombosis. Of these, 12 patients were positive in all LAC assays, five were positive in three LAC assays (negative only with PTT-st (n= 1); negative only with PIT-HB (n=1); negative only with PL dilution (n=2); negative only with KCT (n= 1); one was positive in two LAC assays (PIT-HB and PL dilution); and one was positive only with PL dilution. In seven patients with a history of thrombosis all LAC assays were negative, and six patients with a history of thrombosis were negative for IgG ACA. Of the latter patients, four were negative in all LAC assays and two had four positive LAC assays. Five patients with a history of thrombosis were negative for IgM ACA. Of these, two were negative in all LAC assays and three had four positive LAC assays. Six out of We found a significant relation between the presence of anti-PL antibodies, detected by any of the assays, and a history of thrombosis (Table 2 ; x2 value varying from 5*626 (IgG ACA; p<0-025) to 29*618 (KCT; p<00005)). Table 2 shows the sensitivity, specificity, and detection rate of the anti-PL antibody assays for thrombosis. LAC detected with PTT-HB or PL dilution had the combination of a relatively high sensitivity (65%), specificity (87%), and detection rate (61%). For both IgG-ACA and IgM-ACA high sensitivities were found (¢77%), but specificities (-51%) and detection rates (-33%) were low.
RELATION BETWEEN ANTI-PL ANTIBODIES AND FETAL LOSS
For the 46 women studied with at least one pregnancy, the total number of pregnancies was 105. There was a total of 39 fetal losses (in 19 women). Of these, 12 Table 3 ). The presence of raised ACA levels had a high sensitivity (379%) associated with a low specificity (44%) and detection rate (-52%). A history of fetal loss was present in 3/6 and 5/6 patients with medium or high levels of IgG ACA and IgM ACA respectively.
RELATION BETWEEN HISTORY OF FETAL LOSS AND HISTORY OF THROMBOSIS
Ten out of 19 patients with a history of fetal loss also had a history of thrombosis, whereas 10/13 patients Abbreviations: see Table 1 .
group with a history of both thrombosis and pregnancy had experienced fetal loss. The relation between these parameters was significant (X2=9*483; p<0-005).
RELATION BETWEEN ANTI-PL ANTIBODIES AND PRESENCE OF THROMBOCYTOPENIA
Of the 106 patients studied, 11 had platelet counts below 150x 109/l and four of these below 100x 109/l.
Five of the 11 patients with thrombocytopenia were positive in all anti-PL antibody assays, three were positive in all assays except for IgM ACA, and one patient was negative for LAC with PTT-st and positive in all other anti-PL assays. Two patients were negative in all anti-PL assays except for IgM ACA. A significant relation was found between presence of thrombocytopenia and a positive LAC assay. x2 varied from 5X999 with PIT-st (p<0025) to 23-094 with the KCT (p<00005) ( Table 4 ). LAC detected with the KCT had the highest specificity (83%); the detection rate of all assays was relatively low (-36%) ( Table 4) .
RELATION BETWEEN THE PRESENCE OF THROMBOCYTOPENIA AND HISTORY OF THROMBOSIS
Eight of the 11 patients with thrombocytopenia had a history of thrombosis, whereas a history of fetal loss was present in five of the seven patients with thrombocytopenia who had been pregnant. The presence of thrombocytopenia was sig2nificantly related to a history of thrombosis (X 17-579; p<O0OOO5), but not to a history of fetal loss (X2=3-616).
Discussion
Current data indicate that both LAC and raised ACA levels are markers of a subset of lupus patients with a high prevalence of thrombosis, fetal loss, and thrombocytopenia. ' (19 v 14) are about the same in both studies, but the number of patients with a history of thrombosis is quite different (26 v 60) .
Although the availability of laboratory tests that have a sensitivity of about 50-75% and a specificity of about 80-85% towards thrombosis and fetal loss can indeed be regarded as useful for the characterisation of a particular subset of patients, prospective studies will have to confirm and extend these findings before adequate therapeutic regimens can be advocated for patients with anti-PL antibodies. This is strengthened both by data from a recent prospective study on 50 pregnant patients with SLE, which showed that with raised ACA levels or increased (A)PTT values, respectively 25% or 50% of the pregnancies resulted in live births,34 and by the follow up of two of our patients who have had recorded LAC (both with PTT-HB and PL dilution methods) for at least 10 years but never had thrombosis.
In conclusion, our data show that a panel of LAC assays (PTT-HB; PL dilution; KCT) is useful for the detection of lupus patients with thrombosis, fetal loss, and/or thrombocytopenia, whereas the ACA assay is insufficiently specific for this purpose. 
